drugset / Trial / NCT00242710
Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women
RandomizedParallel-groupDouble-blindPrevention
Summary
The purpose of this study is to determine whether bazedoxifene/conjugated estrogens combinations are effective for the prevention of endometrial hyperplasia and for the prevention of osteoporosis in postmenopausal women.
Timeline
- Start
- 2005-09
- Primary completion
- 2008-09
- Completion
- 2008-09
Outcome
Met primary endpoint
registry Bazedoxifene 20 mg/Conjugated Estrogen 0.45 mg vs Placebo; p <0.001; LS Mean Difference 1.61 (95% CI 0.97 to 2.24); ANCOVA NCT00242710 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bazedoxifene | Other / unclassified | 20 mg | Oral |
| Comparator | MPA | Unknown | 1.5 mg | Oral |
| Subject | conjugated estrogen | Unknown | 0.45 mg | Oral |
| Subject | conjugated estrogen | Unknown | 0.625 mg | Oral |